WT
BMRN icon

Wellcome Trust’s BioMarin Pharmaceuticals BMRN Stock Holding History

Wellcome Trust’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-4,978
Closed -$340K – 34
2014
Q1 		$340K Buy
+4,978
New +$367K 0.01% 34

Other funds holding BMRN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Wellcome Trust's BMRN Position: Q2 2014 in Review

Wellcome Trust sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2014, closing a stake of 4,978 shares — an estimated $340K sold.

Wellcome Trust first reported a position in BMRN in Q1 2014 and held it in 1 quarter. The position peaked at $340K in Q1 2014. 321 funds tracked by Wall St. Rank hold BMRN as of Q2 2014.

  • Wellcome Trust reported no remaining BioMarin Pharmaceuticals position as of Q2 2014 after selling out during the quarter.
  • Wellcome Trust sold 4,978 BioMarin Pharmaceuticals shares in Q2 2014, an estimated $340K.
  • Wellcome Trust first reported a position in BioMarin Pharmaceuticals in Q1 2014 and held it in 1 quarter.
  • Wellcome Trust's BioMarin Pharmaceuticals position peaked at $340K in Q1 2014.
  • 321 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2014.

Based on Wellcome Trust's 13F filing for Q2 2014, filed 23 Jul 2014.